These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8966574)

  • 1. Lipid A: target for antibacterial drugs.
    Vaara M
    Science; 1996 Nov; 274(5289):939-40. PubMed ID: 8966574
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibacterial agents that inhibit lipid A biosynthesis.
    Onishi HR; Pelak BA; Gerckens LS; Silver LL; Kahan FM; Chen MH; Patchett AA; Galloway SM; Hyland SA; Anderson MS; Raetz CR
    Science; 1996 Nov; 274(5289):980-2. PubMed ID: 8875939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbohydroxamido-oxazolidines: antibacterial agents that target lipid A biosynthesis.
    Chen MH; Steiner MG; de Laszlo SE; Patchett AA; Anderson MS; Hyland SA; Onishi HR; Silver LL; Raetz CR
    Bioorg Med Chem Lett; 1999 Feb; 9(3):313-8. PubMed ID: 10091675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
    Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR
    Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.
    Jackman JE; Fierke CA; Tumey LN; Pirrung M; Uchiyama T; Tahir SH; Hindsgaul O; Raetz CR
    J Biol Chem; 2000 Apr; 275(15):11002-9. PubMed ID: 10753902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.
    McAllister LA; Montgomery JI; Abramite JA; Reilly U; Brown MF; Chen JM; Barham RA; Che Y; Chung SW; Menard CA; Mitton-Fry M; Mullins LM; Noe MC; O'Donnell JP; Oliver RM; Penzien JB; Plummer M; Price LM; Shanmugasundaram V; Tomaras AP; Uccello DP
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6832-8. PubMed ID: 23046961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Novel Inhibitors of LpxC Displaying Potent in Vitro Activity against Gram-Negative Bacteria.
    Surivet JP; Panchaud P; Specklin JL; Diethelm S; Blumstein AC; Gauvin JC; Jacob L; Masse F; Mathieu G; Mirre A; Schmitt C; Lange R; Tidten-Luksch N; Gnerre C; Seeland S; Herrmann C; Seiler P; Enderlin-Paput M; Mac Sweeney A; Wicki M; Hubschwerlen C; Ritz D; Rueedi G
    J Med Chem; 2020 Jan; 63(1):66-87. PubMed ID: 31804826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
    Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N
    J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
    Panchaud P; Surivet JP; Diethelm S; Blumstein AC; Gauvin JC; Jacob L; Masse F; Mathieu G; Mirre A; Schmitt C; Enderlin-Paput M; Lange R; Gnerre C; Seeland S; Herrmann C; Locher HH; Seiler P; Ritz D; Rueedi G
    J Med Chem; 2020 Jan; 63(1):88-102. PubMed ID: 31804829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.
    Montgomery JI; Brown MF; Reilly U; Price LM; Abramite JA; Arcari J; Barham R; Che Y; Chen JM; Chung SW; Collantes EM; Desbonnet C; Doroski M; Doty J; Engtrakul JJ; Harris TM; Huband M; Knafels JD; Leach KL; Liu S; Marfat A; McAllister L; McElroy E; Menard CA; Mitton-Fry M; Mullins L; Noe MC; O'Donnell J; Oliver R; Penzien J; Plummer M; Shanmugasundaram V; Thoma C; Tomaras AP; Uccello DP; Vaz A; Wishka DG
    J Med Chem; 2012 Feb; 55(4):1662-70. PubMed ID: 22257165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chiral pool synthesis and biological evaluation of C-furanosidic and acyclic LpxC inhibitors.
    Müller H; Gabrielli V; Agoglitta O; Holl R
    Eur J Med Chem; 2016 Mar; 110():340-75. PubMed ID: 26866455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of potent Gram-negative specific LpxC inhibitors.
    Mansoor UF; Vitharana D; Reddy PA; Daubaras DL; McNicholas P; Orth P; Black T; Siddiqui MA
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1155-61. PubMed ID: 21273067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoxazole-3-hydroxamic acid derivatives as peptide deformylase inhibitors and potential antibacterial agents.
    Calí P; Naerum L; Mukhija S; Hjelmencrantz A
    Bioorg Med Chem Lett; 2004 Dec; 14(24):5997-6000. PubMed ID: 15546716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput catch-and-release synthesis of oxazoline hydroxamates. Structure-activity relationships in novel inhibitors of Escherichia coli LpxC: in vitro enzyme inhibition and antibacterial properties.
    Pirrung MC; Tumey LN; McClerren AL; Raetz CR
    J Am Chem Soc; 2003 Feb; 125(6):1575-86. PubMed ID: 12568618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
    Cuny GD
    Expert Opin Ther Pat; 2009 Jun; 19(6):893-9. PubMed ID: 19473108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonamide-based non-alkyne LpxC inhibitors as Gram-negative antibacterial agents.
    Kawai T; Kazuhiko I; Takaya N; Yamaguchi Y; Kishii R; Kohno Y; Kurasaki H
    Bioorg Med Chem Lett; 2017 Feb; 27(4):1045-1049. PubMed ID: 28082037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of triazolyl-substituted benzyloxyacetohydroxamic acids as LpxC inhibitors.
    Hoff K; Mielniczuk S; Agoglitta O; Iorio MT; Caldara M; Bülbül EF; Melesina J; Sippl W; Holl R
    Bioorg Med Chem; 2020 Jul; 28(13):115529. PubMed ID: 32386952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of a carbohydrate-derived hydroxamic acid inhibitor of the bacterial enzyme (LpxC) involved in lipid A biosynthesis.
    Li X; Uchiyama T; Raetz CR; Hindsgaul O
    Org Lett; 2003 Feb; 5(4):539-41. PubMed ID: 12583763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
    Mdluli KE; Witte PR; Kline T; Barb AW; Erwin AL; Mansfield BE; McClerren AL; Pirrung MC; Tumey LN; Warrener P; Raetz CR; Stover CK
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2178-84. PubMed ID: 16723580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups.
    Pirrung MC; Tumey LN; Raetz CR; Jackman JE; Snehalatha K; McClerren AL; Fierke CA; Gantt SL; Rusche KM
    J Med Chem; 2002 Sep; 45(19):4359-70. PubMed ID: 12213077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.